Department of Human Anatomy, Histology and Embryology, School of Biology and Basic Medical Sciences, Soochow University, Suzhou 215007, China.
School of Medicine, Yangzhou University, Yangzhou 225001, China.
Int Immunopharmacol. 2019 Oct;75:105783. doi: 10.1016/j.intimp.2019.105783. Epub 2019 Jul 31.
Myrothecine A, characterized from the extracts of myrothecium roridum strain IFB-E012, isolated as endophytic fungi found in the traditional Chinese medicinal plant Artemisia annua. Here we investigated its roles on anti-tumor and immune regulation in vitro. Dendritic cells (DCs) are the most potent antigen presenting cells in immune responses. Recent studies have indicated that miRNAs are indispensable in regulating the development, differentiation, maturation and function of DC. MiR-221, acted as an oncogene, is an important regulator in cancer development by binding to 3' untranslated regions (3' UTR) of target mRNA. Here, we investigated whether myrothecine A could inhibit cell proliferation in hepatocellular carcinoma (HCC) cell line SMMC-7721 by regulating miR-221. The HCC cells were treated with myrothecine A at different concentration, and the cell growth ability was measured by MTT assay. Then we observed whether myrothecine A could affect the maturation of DC by regulating miR-221. The HCC cell line was co-cultured with immature DC from mice bone marrow, and the levels of CD86 and CD40 was detected by FCM. Our results showed that myrothecine A could rescue miR-221-induced cell proliferation and influence the protein level of p27 by inhibiting the expression of miR-221. In addition, myrothecine A could enhance the expression of CD86 and CD40 by reversing the function of miR-221. Therefore, myrothecine A may be acted as an anti-tumor drug to promote the maturation of DC in the microenvironment of hepatocellular carcinoma.
米罗替宁 A,从内生真菌米曲霉 IFB-E012 的提取物中分离得到,发现于传统中药青蒿中。在这里,我们研究了它在体外抗肿瘤和免疫调节中的作用。树突状细胞(DC)是免疫反应中最有效的抗原提呈细胞。最近的研究表明,miRNA 在调节 DC 的发育、分化、成熟和功能方面不可或缺。miR-221 作为一种癌基因,通过与靶 mRNA 的 3'非翻译区(3'UTR)结合,是癌症发展的重要调节因子。在这里,我们研究了米罗替宁 A 是否可以通过调节 miR-221 来抑制肝癌细胞系 SMMC-7721 的细胞增殖。用不同浓度的米罗替宁 A 处理 HCC 细胞,通过 MTT 法测定细胞生长能力。然后观察米罗替宁 A 是否可以通过调节 miR-221 来影响 DC 的成熟。将 HCC 细胞系与从小鼠骨髓中获得的未成熟 DC 共培养,并通过 FCM 检测 CD86 和 CD40 的水平。我们的结果表明,米罗替宁 A 可以通过抑制 miR-221 的表达来挽救 miR-221 诱导的细胞增殖,并影响 p27 的蛋白水平。此外,米罗替宁 A 可以通过逆转 miR-221 的功能增强 CD86 和 CD40 的表达。因此,米罗替宁 A 可能作为一种抗肿瘤药物,在肝癌微环境中促进 DC 的成熟。